Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, France.
J Infect Dis. 2012 Jul 15;206(2):212-9. doi: 10.1093/infdis/jis328. Epub 2012 May 2.
West Nile virus (WNV) is a mosquito-borne flavivirus that emerged in North America and caused numerous cases of human encephalitis, thus urging the development of a vaccine. We previously demonstrated the efficacy of a recombinant measles vaccine (MV) expressing the secreted form of the envelope glycoprotein from WNV to prevent WNV encephalitis in mice. In the present study, we investigated the capacity of this vaccine candidate to control WNV infection in a primate model. We first established experimental WNV infection of squirrel monkeys (Saimiri sciureus). A high titer of virus was detected in plasma on day 2 after infection, and viremia persisted for 5 days. A single immunization of recombinant MV-WNV vaccine elicited anti-WNV neutralizing antibodies that strongly reduced WNV viremia at challenge. This study demonstrates for the first time the capacity of a recombinant live attenuated measles vector to protect nonhuman primates from a heterologous infectious challenge.
西尼罗河病毒（WNV）是一种蚊媒黄病毒，它出现在北美并导致了许多人类脑炎病例，因此促使了疫苗的开发。我们之前证明了表达 WNV 包膜糖蛋白分泌形式的重组麻疹疫苗（MV）在预防小鼠 WNV 脑炎方面的有效性。在本研究中，我们研究了这种候选疫苗在灵长类动物模型中控制 WNV 感染的能力。我们首先建立了松鼠猴（Saimiri sciureus）的实验性 WNV 感染。感染后第 2 天，血浆中检测到高滴度的病毒，病毒血症持续 5 天。单次接种重组 MV-WNV 疫苗可诱导出抗 WNV 的中和抗体，强烈降低了攻毒时的 WNV 病毒血症。这项研究首次证明了重组减毒麻疹载体能够保护非人类灵长类动物免受异源感染挑战。
